



**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**[Docket No. DEA-626]**

**Importer of Controlled Substances Application: Alcami Carolinas Corporation**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before **[INSERT 30 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER]**. Such persons may also file a written request for a hearing on the application on or before **[INSERT 30 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER]**.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on March 13, 2020, Alcami Carolinas Corporation, 1726 North 23<sup>rd</sup> Street, Wilmington, North Carolina 28405-1822 applied to be registered as an importer of the following basic class(es) of controlled substances:

<b>Controlled Substance</b>	<b>Drug Code</b>	<b>Schedule</b>
Psilocybin	7437	I
Psilocyn	7438	I
Thebaine	9333	II
Pentobarbital	2270	II

The company plans to import the listed controlled substances in bulk for the manufacturing of capsules/tablets for Phase II clinical trials. Approval of permit applications will occur only when the registrant's activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA-approved or non-approved finished dosage forms for commercial sale.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020-09552 Filed: 5/4/2020 8:45 am; Publication Date: 5/5/2020]